![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Meiji Seika Pharma Co., Ltd. Tokyo Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Doxorubicin Hydrochloride, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2003-151 - Rev 03
This Chemical Type CEP, issued on April 02, 2020, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 714 associated with this CEP further emphasizes